Tzach Nahumi, Practice Chinese medicine and use Acupuncture & Herbs.

Head of the Integrative Medicine Service in the Oncology Department in Bnai Zion Medical Center.

Dr. Eberhardt graduated from the University of Essen Medical School in 1984 and trained in Internal Medicine and Endoscopy. In 1989, he transferred to the West German Cancer Centre (WGCC) at University Hospital Duisburg-Essen, where he obtained his doctoral degree. Dr. Eberhardt joined the Multidisciplinary Thoracic Oncology Group at WGCC in 1991, becoming the leader of this group in 1997. He has been a Consultant in Medical Oncology and a Senior Physician in the Outpatient Unit at WGCC since 2004. In 2007, he was appointed as Associate Director for Regional Outreach at WGCC and served as such until 2013. In 2019 her received his venia legendi in Internal Medicine and became Private Lecturer (Priv.-Doz.) at the Medical Faculty of the University Duisburg-Essen.

Dr. Eberhardt’s primary research interests are multimodality treatment and novel molecular targeted agents in thoracic oncology. He has been a Principal Investigator in several local, national and international clinical trials and was the Clinical Trials Coordinator for two major German Krebshilfe multicentre clinical trials in Germany.

Dr.  Eberhardt is an active member of several national and international research societies. He is a past-member of the Lung Cancer Track of the American Society of Clinical Oncology (ASCO) Scientific Program Committee (2006–2008 and 2010–2013), and served as Speaker of the Lung Cancer Track of the Arbeitsgemeinschaft Internistische Onkologie (Medical Oncology Working Group of the German Cancer Society) from 2009 until 2014. He is also a member of the European Society for Medical Oncology (ESMO) Thoracic Oncology Faculty. He served as Chair (2004–2006) and Past-Chair (2006–2007) of the International Association for the Study of Lung Cancer (IASLC) Educational Committee. In 2007, he was elected to the IASLC Board of Directors and served on the board until 2011.

He is Associate Editor for the Journal of Thoracic Oncology and is a reviewer for several other high-ranked oncological and lung cancer journals. He has authored/co-authored more than 180 scientific articles in clinical and translational cancer research

Yuval Shaked (PhD) is a Professor at the Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel, and the director of the Technion Integrated Cancer Center (TICC). He obtained his PhD from the Department of Neurology at Hadassah University Hospital (Israel) where he studied biochemical aspects of neurodegenerative disorders. Subsequently, he was trained at Sunnybrook Health Sciences Centre, University of Toronto, Canada, and studied cancer biology and therapy under the supervision of Prof. Robert S. Kerbel. In 2008, Prof. Shaked, started his own independent career at a rank of Assistant Professor in the Faculty of Medicine, Technion, Israel. In his research, Prof. Shaked has pioneered the idea that the host in response to therapy alters the tumor microenvironment sometimes to the tumor advantage, therefore suggesting a double-edged sword of cancer therapy. In 2013 he was promoted to associate professor and in 2018 to a full professor. He served as the vice dean for research in his faculty and he currently serves as a head of the Technion- integrated cancer center. Prof. Shaked received a number of awards including the Yigal Allon fellowship, Krill Prize from the Wolf foundation and Youdim prize for Excellence in Cancer Research. He is supported by national and European grant agencies including ISF and ERC. Prof. Shaked is an author of over 120 published studies.

• Homepage: https://shakedlab.net.technion.ac.il/
• Publications: https://www.ncbi.nlm.nih.gov/pubmed/?term=shaked+yuval
• ORCID: https://orcid.org/0000-0001-9037-3895